Revised study plan for NeoFox Phase 2 clinical trial with Foxy-5, resulting in time and cost savings
Following the reported observations of the unexpectedly positive effects of Foxy-5 in colon cancer, the study plan for the phase 2 NeoFox trial is now being revised. The change means that new endpoints will be introduced, leading to a significantly shorter time to readout of initial efficacy measures.As a result of the confirmed observations, intensive activity is now underway to revise the NeoFox study plan. Treatment with the drug candidate Foxy-5 will be adjusted to take place only for three weeks before surgery. There will be no further treatment with Foxy-5 after surgery, as the focus